Results 161 to 170 of about 9,189 (185)
Some of the next articles are maybe not open access.
Aztreonam-avibactam for the treatment of intra-abdominal infections
Expert Opinion on PharmacotherapyIntra-abdominal infections are becoming increasingly common and can lead to significant morbidity and mortality. The incidence of these infections due to resistant gram-negative organisms is also increasing. Given this resistance, new antibiotic combinations are being developed, often utilizing older antibiotics and newer β-lactamase inhibitors ...
Hannah Delp +2 more
openaire +2 more sources
The Combination of Aztreonam-Avibactam in Multidrug-Resistant Gram-Negative Infections
Annals of PharmacotherapyObjective: Aztreonam-avibactam (ATM-AVI) is used for difficult-to-treat gram-negative infections. The objective of this review is to analyze the pharmacology, safety, and clinical application of ATM-AVI. Data sources: PubMed, Embase ...
Maria Roye-Azar +3 more
openaire +2 more sources
Microbial Drug Resistance
Aztreonam/avibactam (ATM/AVI) has been recently approved drug for clinical use in the European Union. The aim of this study was to develop and evaluate a novel selective medium for the isolation of ATM/AVI-resistant strains (Super ATM/AVI selective medium) to help to control their spread.
Herrera-Espejo, Soraya +5 more
openaire +3 more sources
Aztreonam/avibactam (ATM/AVI) has been recently approved drug for clinical use in the European Union. The aim of this study was to develop and evaluate a novel selective medium for the isolation of ATM/AVI-resistant strains (Super ATM/AVI selective medium) to help to control their spread.
Herrera-Espejo, Soraya +5 more
openaire +3 more sources
International Journal of Antimicrobial Agents
Aztreonam-avibactam is a new combination antibiotic with a broad spectrum of activity against Enterobacterales and lactose non-fermenting Gram-negative bacteria. We evaluated the available data on resistance to aztreonam-avibactam.We performed a thorough search of four databases for studies that included data on the antimicrobial susceptibility of ...
Matthew E. Falagas +3 more
openaire +2 more sources
Aztreonam-avibactam is a new combination antibiotic with a broad spectrum of activity against Enterobacterales and lactose non-fermenting Gram-negative bacteria. We evaluated the available data on resistance to aztreonam-avibactam.We performed a thorough search of four databases for studies that included data on the antimicrobial susceptibility of ...
Matthew E. Falagas +3 more
openaire +2 more sources
Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
The Medical Letter on Drugs and TherapeuticsThe FDA has approved Emblaveo (Abbvie), an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated intra-abdominal infections (cIAIs) in adults.
openaire +2 more sources
The Journal of Antibiotics
Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor.
openaire +2 more sources
Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor.
openaire +2 more sources
International Journal of Antimicrobial Agents
Aztreonam-avibactam (ATM-AVI) is a promising β-lactam/β-lactamase inhibitor combination with an antimicrobial spectrum covering serine carbapenemase- or metallo-β-lactamase-producing Enterobacterales. Although ATM-AVI has not been widely used in clinical practice, resistance to it in Escherichia coli has been widely reported.
Xinli Xiang +6 more
openaire +2 more sources
Aztreonam-avibactam (ATM-AVI) is a promising β-lactam/β-lactamase inhibitor combination with an antimicrobial spectrum covering serine carbapenemase- or metallo-β-lactamase-producing Enterobacterales. Although ATM-AVI has not been widely used in clinical practice, resistance to it in Escherichia coli has been widely reported.
Xinli Xiang +6 more
openaire +2 more sources
[Role of aztreonam/avibactam in antibiotic therapy].
Klinicka mikrobiologie a infekcni lekarstviThe article reviews current options for the treatment of infections caused by carbapenemase-producing Enterobacterales, including the role of aztreonam/avibactam.
openaire +1 more source
Drugs
Aztreonam-avibactam (Emblaveo™), a fixed-dose combination of the monobactam antibacterial agent aztreonam and the broad-spectrum β-lactamase inhibitor avibactam, has been developed as a treatment, administered intravenously, for serious bacterial infections caused by aerobic Gram-negative organisms. In the EU, aztreonam-avibactam is indicated in adults
openaire +2 more sources
Aztreonam-avibactam (Emblaveo™), a fixed-dose combination of the monobactam antibacterial agent aztreonam and the broad-spectrum β-lactamase inhibitor avibactam, has been developed as a treatment, administered intravenously, for serious bacterial infections caused by aerobic Gram-negative organisms. In the EU, aztreonam-avibactam is indicated in adults
openaire +2 more sources